In comparison to PD-L1 monotherapy, combined CTLA-4 and PD-L1 blockade resulted in only moderate treatment effects (though not statistically significant) on tumor shrinkage and T-cell activation and migration i.e., a greater number of GFP+ T-cells and populations of cells with higher velocities were measured in tumors given both antibodies. Here, CTLA4 is linked to neoplasm.